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Abstract Remyelination promoting human IgMs effectively increase the number of myelinated axons in animal
models of multiple sclerosis. Hence, they ultimately stimulate myelin production by oligodendrocytes
(OLs); however, their exact mechanism of action remains to be elucidated, and in particular, it remains
unclear whether they are directly targeting OLs, or their action is mediated by effects on other cell types.
We assessed the effect of remyelination promoting antibody rHIgM22 on the proliferative response and on
the ceramide/sphingosine 1-phosphate rheostat in mixed glial cell cultures (MGCs). rHIgM22 treatment
caused a time-dependent increase in PDGFαR protein in MGCs. Forty-eight hours of treatment with
rHIgM22 induced a dose-dependent proliferative response (evaluated as total cell number and as EdU(+)
cell number) in MGCs. When the proliferation response of MGCs to rHIgM22 was analyzed as a function
of the cell types, the most significant proliferative response was associated with GLAST(+) cells, i.e.,
astrocytes. In many cell types, the balance between different sphingolipid mediators (the “sphingolipid
rheostat”), in particular ceramide and sphingosine 1-phosphate, is critical in determining the cell fate.
rHIgM22 treatment in MGCs induced a moderate but significant inhibition of total acidic
sphingomyelinase activity (measured in vitro on cell lysates), the main enzyme responsible for the
stimulus-mediated production of ceramide, when treatment was performed in serum containing medium,
but no significant differences were observed when antibody treatment was performed in the absence of
serum. Moreover, rHIgM22 treatment, either in the presence or in absence of serum, had no effects on
ceramide levels. On the other hand, rHIgM22 treatment for 24 h induced increased production and release
of sphingosine 1-phosphate in the extracellular milieu of MGC. Release of sphingosine 1-phosphate upon
rHIgM22 treatment was strongly reduced by a selective inhibitor of PDGFαR. Increased sphingosine 1-
phosphate production does not seem to be mediated by regulation of the biosynthetic enzymes, sphingosine
kinase 1 and 2, since protein levels of these enzymes and phosphorylation of sphingosine kinase 1 were
unchanged upon rHIgM22 treatment. Instead, we observed a significant reduction in the levels of
sphingosine 1-phosphate lyase 1, one of the key catabolic enzymes. Remarkably, rHIgM22 treatment under
the same experimental conditions did not induce changes in the production and/or release of sphingosine 1-
phosphate in pure astrocyte cultures. Taken together, these data suggest that rHIgM22 indirectly influences
the proliferation of astrocytes in MGCs, by affecting the ceramide/sphingosine 1-phosphate balance. The
specific cell population directly targeted by rHIgM22 remains to be identified, however our study unveils
another aspect of the complexity of rHIgM22-induced remyelinating effect.
Keywords (separated by '-') rHIgM22 - Multiple sclerosis - Remyelination - Sphingolipids
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Abstract
Remyelination promoting human IgMs effectively increase the number of myelinated axons in animal models of multiple 
sclerosis. Hence, they ultimately stimulate myelin production by oligodendrocytes (OLs); however, their exact mechanism 
of action remains to be elucidated, and in particular, it remains unclear whether they are directly targeting OLs, or their 
action is mediated by effects on other cell types. We assessed the effect of remyelination promoting antibody rHIgM22 on the 
proliferative response and on the ceramide/sphingosine 1-phosphate rheostat in mixed glial cell cultures (MGCs). rHIgM22 
treatment caused a time-dependent increase in PDGFαR protein in MGCs. Forty-eight hours of treatment with rHIgM22 
induced a dose-dependent proliferative response (evaluated as total cell number and as EdU(+) cell number) in MGCs. When 
the proliferation response of MGCs to rHIgM22 was analyzed as a function of the cell types, the most significant proliferative 
response was associated with GLAST(+) cells, i.e., astrocytes. In many cell types, the balance between different sphingolipid 
mediators (the “sphingolipid rheostat”), in particular ceramide and sphingosine 1-phosphate, is critical in determining the 
cell fate. rHIgM22 treatment in MGCs induced a moderate but significant inhibition of total acidic sphingomyelinase activity 
(measured in vitro on cell lysates), the main enzyme responsible for the stimulus-mediated production of ceramide, when 
treatment was performed in serum containing medium, but no significant differences were observed when antibody treatment 
was performed in the absence of serum. Moreover, rHIgM22 treatment, either in the presence or in absence of serum, had 
no effects on ceramide levels. On the other hand, rHIgM22 treatment for 24 h induced increased production and release of 
sphingosine 1-phosphate in the extracellular milieu of MGC. Release of sphingosine 1-phosphate upon rHIgM22 treatment 
was strongly reduced by a selective inhibitor of PDGFαR. Increased sphingosine 1-phosphate production does not seem to 
be mediated by regulation of the biosynthetic enzymes, sphingosine kinase 1 and 2, since protein levels of these enzymes 
and phosphorylation of sphingosine kinase 1 were unchanged upon rHIgM22 treatment. Instead, we observed a significant 
reduction in the levels of sphingosine 1-phosphate lyase 1, one of the key catabolic enzymes. Remarkably, rHIgM22 treatment 
under the same experimental conditions did not induce changes in the production and/or release of sphingosine 1-phosphate 
in pure astrocyte cultures. Taken together, these data suggest that rHIgM22 indirectly influences the proliferation of astro-
cytes in MGCs, by affecting the ceramide/sphingosine 1-phosphate balance. The specific cell population directly targeted 
by rHIgM22 remains to be identified, however our study unveils another aspect of the complexity of rHIgM22-induced 
remyelinating effect.
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ASM  Acid sphingomyelinase
BSA  Bovine serum albumin
Cer  Ceramide
CNS  Central nervous system
CSF  Cerebrospinal fluid
MGCs  Mixed glial cultures
MS  Multiple sclerosis
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OPCs  Oligodendrocyte precursor cells
SGPL1  Sphingosine 1-phosphate lyase 1
SK  Sphingosine kinase
SK1  Sphingosine kinase 1




SPP1  Sphingosine 1-phosphate phosphatase 1
S1P  Sphingosine 1-phosphate
Introduction
Multiple sclerosis (MS) is primarily considered an autoim-
mune disease, i.e. a disease caused by an adaptive immune 
response to self-antigens, implying the activation and 
recruitment of myelin-reactive immune cells (T-cells) from 
the periphery to the CNS. However, oligodendrocyte death 
and myelin loss is clearly observed in early lesions of MS 
even in the absence of T- or B-cells infiltrates, and activation 
and proliferation of microglia and astrocytes is consistently 
observed in demyelinating lesions, suggesting that innate 
immune system contribution by these CNS-resident cells 
might play a relevant role in the disease [1].
Astrocytes and microglia play dual roles in the initia-
tion and progression of most neurological disorders, and in 
MS lesion development. Both cell types are key players in 
driving CNS inflammation and are directly implicated in 
the pathophysiology of MS, as suggested from studies on 
patients’ tissues, in animal models of the disease and in vitro 
(reviewed in [2, 3]).
Despite the prevailing view of reactive astrocytes and of 
activated (“classically activated”) microglia as impeding 
regenerative processes in the CNS, “activated” (cytokine-
activated) astrocytes within lesions might also limit the det-
rimental effects of pro-inflammatory factors, thus providing 
support and protection for oligodendrocytes and neurons and 
creating a permissive environment for remyelination. In par-
ticular, astrocytes play important roles in maintaining the 
homeostasis and spatial distribution of different secreted fac-
tors that determine oligodendrocyte precursor cells (OPCs) 
proliferation, migration and differentiation [4]. Pro-inflam-
matory cytokines (IL-1β and TGFβ1) induced the produc-
tion of IL-11 in cultured astrocytes, and IL-11 production 
was upregulated in astrocytes in MS lesions. IL-11 enhanced 
oligodendrocyte survival and maturation, and increased 
myelin formation in rodent CNS co-cultures [5]. IL-1β also 
stimulated the production of the chemokine CXCL1 (GRO-
alpha), and CXCL1 produced by hypertrophic astrocytes in 
MS lesions seems to represent a mechanism for recruitment 
of oligodendrocytes to damaged area, a prerequisite for 
remyelination [6]. In the murine cuprizone model of toxic 
demyelination, IGF-1 and CNTF were elevated in astrocytes 
in lesion areas, while GDNF, IGF-1 and FGF were upregu-
lated in microglia [7]. Similar to astrocytes, “alternatively 
activated” microglia within MS lesions show a beneficial, 
neuroprotective profile. In particular, activation of microglial 
phagocytosis at the lesion site seems to be crucial in order 
to remove damaged myelin debris [8], which can inhibit 
myelin repair. In this sense, an important role of rHIgM22, 
the remyelination-promoting antibody object of this study, 
has been recently described [9]. rHIgM22 was indeed able 
to stimulate myelin phagocytosis in a mouse microglial cell 
line and primary rat microglia, in a complement receptor-
dependent manner that was fully inhibited by use of comp-
statin to block complement factor 3 (C3) cleavage by C3 
convertase. Remarkably, astrocyte and microglia functions 
in this sense are interdependent and coordinated.
Some convincing lines of evidence point out that the 
switch between detrimental versus protective phenotype 
of astrocytes in MS can be due to the opposing effect of 
sphingolipid mediators, and that sphingolipid metabolism 
and sphingolipid-dependent signaling might be the target of 
factors able to modify astrocyte phenotype in a protective 
way for MS.
Increased production of the pro-apoptotic sphingolipid 
ceramide might contribute to oligodendrocyte damage in 
MS. Ceramide synergistically with TNF was able to induce 
apoptosis in cultured oligodendrocytes [10]. Ceramide 
accumulated in reactive astrocytes in active lesions of MS 
in humans, and in the cuprizone mouse model of demyeli-
nation. Concomitantly, sphingosine had accumulated and 
sphingosine 1-phosphate (S1P) levels were decreased [11]. 
Sphingosine kinase 1 (SK1) and the  S1P3 receptor are upreg-
ulated in reactive astrocytes in MS lesions, or in cultured 
rat astrocytes treated with the pro-inflammatory molecule 
LPS. On the other hand, S1P induced secretion of CXCL1 
in astrocytes. Thus, the SK1/S1P3 pathway seems to be 
relevant for astrocyte activation. However, S1P-dependent 
astrocyte activation could play a dual role in the context of 
MS. On one hand, it could represent a detrimental event, 
enhancing astrogliosis, on the other hand, it could be ben-
eficial, through increased remyelination sustained by the 
release of CXCL1 or other trophic factors from activated 
astrocytes [12–14]. Fingolimod, the only approved oral 
disease-modifying therapy for relapsing remitting MS (RR-
MS), is phosphorylated in vivo to fingolimod-P, a structural 
analog of S1P. Fingolimod is effective in MS by blocking 
the migration of immune cells and preventing the invasion 
of auto-aggressive T-cells into the CNS.
However, emerging evidence indicates that Fingolimod 
has direct effects in the CNS in MS, and points out the 
importance of astrocytes in direct CNS effects of Fingoli-
mod. In vitro, fingolimod stimulates astrocyte migration, 
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 S1P1. In EAE, Fingolimod is highly effective but its efficacy 
is lost in animals selectively deficient for  S1P1 in astrocytes 
(while still having normal immunological receptor expres-
sion and functions) [13, 14].
Strategies aimed at enhancing endogenous myelin repair 
by stimulating the resident myelin-producing cells seem 
to be a promising approach to prevent or slow down the 
progression of MS. Among novel reagents under develop-
ment to this aim, remyelination-promoting human IgMs 
are very attractive. rHIgM22 is the recombinant form of 
a human IgM identified from a patient with Waldenström 
macroglobulinemia. rHIgM22 was able to bind to myelin 
and to the surface of mature, O4-positive oligodendrocytes 
in vitro [15], and to enhance remyelination in three differ-
ent mouse models of demyelination, i.e. Theiler’s murine 
encephalomyelitis virus (TMEV) [15, 16], lysolecithin- [17] 
and cuprizone-induced demyelination models [18, 19]. A 
16-site phase 1 clinical trial in patients with MS was com-
pleted in 2015 (NCT0183867), showing no dose-limiting 
toxicities, no serious treatment-emergent adverse events, 
and detectable levels of rHIgM22 in the CSF in all patients. 
Another phase 1 clinical trial in patients with acute relapses 
(NCT02398461) is ongoing. Despite these encouraging 
results, the exact mechanism of action of rHIgM22 remains 
to be elucidated, and some evidence suggests that its effect 
on myelin repair by OLs might be mediated by the involve-
ment of other cell types in the lesion niche. Indeed, rHIgM22 
induced OPC proliferation by activating PDGFαR in mixed 
glial cultures, but not in isolated OPCs, suggesting that the 
stimulation of OPC proliferation by rHIgM22 requires fac-
tors produced by astrocytes and/or microglia [20]. Here we 
demonstrate that rHIgM22 treatment was able to induce 
astrocyte proliferation and S1P production in mixed glial 
cultures. rHIgM22-induced release of S1P in mixed glial 
cultures was reduced in the presence of a selective inhibitor 
of PDGFαR. On the other hand, rHIgM22 had no effect on 
S1P production in pure astrocyte cultures, suggesting that a 
complex cross talk between different cell types is underlying 
the ultimate myelin repair effect elicited by this antibody.
Materials and Methods
Materials
All reagents were of analytical grade.  Ca2+ and  Mg2+-free 
HBSS, d-Glucose, BSA fraction V, HEPES, trypsin, sodium 
pyruvate, poly-d-lysine, PBS,  Na3VO4,  MgSO4, DNase I, 
methanol, chloroform, sphingomyelin (SM) were purchased 
from Sigma Aldrich (Darmstadt, Germany); penicillin/strep-
tomycin, bovine fetal serum, DMEM high glucose, and 
glutamine from Euroclone Spa (Pero, Milan, Italy). The 
antibodies anti-PDGFR, anti-SK1, and goat anti-mouse 
or goat anti-rabbit horseradish peroxidase-linked second-
ary antibodies were from Cell Signaling Technology, Inc. 
(Danvers, MA, USA). Anti-SK2, anti-SGPL1 and anti-
SPP1 antibodies were from Abcam (Cambridge, UK). Anti-
phosphoSK1  (Ser225) antibody was from ECM Biosciences 
(Versailles, KY, USA). Anti-GAPDH was from Sigma 
Aldrich (Darmstadt, Germany). LiteABlot Plus and LiteA-
Blot Turbo Chemiluminescent Substrate were purchased 
from Euroclone Spa (Pero, Milan, Italy). d-Erythro-[3-3H]
sphingosine  ([3H]Sph) was from Perkin Elmer (Boston, MA, 
USA). [1-3H]sphingosine (radiochemical purity over 98%; 
specific radioactivity of 1.36 Ci/mmol) was prepared by spe-
cific chemical oxidation of the primary hydroxyl group of 
sphingosine followed by reduction with sodium  boro[3H]
hydride as previously described [21]. High performance thin 
layer chromatography (HPTLC) silica gel plates and sol-
vents were purchased from Merck (Darmstadt, Germany). 
 [3H]-sphingomyelin, isotopically labelled at the sphingosine 
moiety, was synthesized and purified in our laboratories 
[22].
Human IgM from human serum has been purchased from 
Sigma Aldrich; rHIgM22 antibody was provided by Acorda 
Therapeutics, Inc. (Ardsley, NY, USA).
Mixed Glial Cells (MGCs) and Astrocytes Cell Culture
MGCs were prepared according to Watzlawik et al. [20]. 
Briefly, the hemispheres from P1 to P2 C57BL/6N mice 
or from P1 to P2 Sprague Dawley rats were minced with a 
surgical blade and incubated for 30 min at 37 °C in 0.05% 
trypsin in modified HBSS  (Ca2+ and  Mg2+-free HBSS 
containing 5 g/L d-glucose, 3 g/L BSA fraction V, 20 mM 
HEPES, 100 U/mL penicillin and 100 µg/mL streptomycin). 
Following the addition of  MgSO4 and DNase I, the sample 
was centrifuged at 200×g at 8 °C for 5 min and resuspended 
in modified HBSS. The tissue was further dissociated by 
trituration through a sterile flame narrowed glass pipette, 
centrifuged at 200×g at 8 °C for 10 min, resuspended in 
culture medium and plated on Petri dishes or T75 flasks 
coated with poly-d-lysine (25 µg/mL). The cells were cul-
tured in DMEM high glucose containing 10% heat inacti-
vated FBS, 100 U/mL penicillin, 100 µg/mL streptomycin, 
1 mM sodium pyruvate, and 2 mM glutamine and the culture 
medium changed every 3–4 days.
Purified astrocytes were obtained from MGCs using a 
modified version of the protocol from McCarthy and de Vel-
lis [23]. Briefly, MGCs were cultured for 8–10 days to allow 
the stratification of astrocytes and oligodendrocytes before 
being subjected to a shaking procedure (20 h, 200 rpm). This 
procedure, which removes oligodendrocytes and microglia, 
was repeated three times, allowing a week to pass between 
each shaking. Astrocytic cell layers were then detached using 
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cultured for two weeks in DMEM high glucose containing 
10% heat inactivated FBS, 100 U/mL penicillin, 100 µg/mL 
streptomycin, 1 mM sodium pyruvate, and 2 mM glutamine.
EdU‑Incorporation Assay
MGCs were prepared as described above. For measurements 
of DNA synthesis, metabolic labeling was performed using 
the uridine analog 5-ethynyl-2-deoxyuridine (EdU). Cell 
suspensions were washed by centrifugation for 5 min, 200×g 
and plated at 7 × 104 cells per well on poly-d-lysine-coated 
48 well dish (50 µg/mL poly-d-lysine for 1 h at room temper-
ature (RT) and subsequently washed twice with water). The 
cells were maintained in DMEM/10% FBS for 5 days. After 
5 days in culture, cells were washed twice with DMEM/F12 
and switched to modified DMEM/F12 media supplemented 
with N2 supplement (1:100), 2 mM GlutaMax, penicillin/
streptomycin and 0.1% BSA. Either rHIgM22 or human 
IgM isotype control was added at a concentration range of 
1–50 µg/mL on day 5. All treatments were performed in trip-
licate. PDGF and FGF-2 (Growth Factors at 10 ng/mL each) 
were added on day 6. EdU was added to MGCs at the end 
of day 6 at a final concentration of 10 µM for an additional 
18 h. At the end of the experiment, cells were processed for 
image analysis or flow cytometric analysis.
MGC Flow Cytometry Methods
Following the 48 h of treatment with IgM22 (1.25, 5.0 or 
20 µg/mL), isotype control (20 µg/mL), serum-free media/
vehicle (PBS), or growth media, culture supernatants (non-
adherent cells) were transferred to collection tubes and 
adherent cells were lifted from the wells of a 48-well plate by 
addition of 0.25 mL of prewarmed StemPro™ Accutase™ 
(#A1110501; Thermo Fisher). Plates were incubated for 
5 min at 37 °C and wells were rinsed twice with 0.5 mL of 
PBS containing 1% BSA, w/v, (1% BSA/PBS). The recov-
ered cells were combined with corresponding culture super-
natant and pelleted by centrifuging at 800×g for 5 min at 
4 °C, washed with 1.0 mL 1%BSA/PBS and resuspended in 
200 µL of 1%BSA/PBS. For each labeling condition, 75 µL 
of cells was transferred to clean tube for triple labeling with 
A2B5/CD11bc/GLAST or O4/CD11bc/GLAST antibodies 
(Anti-A2B5-PE, #130-093-581; Anti-O4-PE, #130-095-887; 
Anti-GLAST(ACSA-1)-APC, #130-095-814; Anti-CD11b/
c-PE-Vio770, 130-105-276; Miltenyi Biotec, Germany).
Labeling antibodies were added to the recovered live 
cells for a final dilution of 1 to 10 for immunophenotyping 
(10 µg/mL final concentration). Cells were labeled at 4 °C 
for 20 min, washed twice with 1.0 mL of 1% BSA/PBS, 
pelleted, and resuspended in 100 µL of 1% BSA/PBS. In 
addition to the triple labeled cell populations, conditions 
of single antibody labeled MGCs and Fluorescence Minus 
One controls (samples labelled with 2 of 3 antibodies) were 
prepared to establish compensation values for correction 
of fluorescence signal crossover in samples labeled with 
multiple fluorophores, and for setting fluorescence signal 
thresholds for detection of the positive marker populations. 
The remaining unlabeled cell population (50 µL) was labeled 
with propidium iodide (#556463, BD Pharmingen™) to 
establish gating areas for the singlet, healthy cell popula-
tion. Following labeling, cells were immediately analyzed 
in the live state by flow cytometry.
For identification of cells undergoing DNA replication 
during treatment, a Click-iT™ Plus EdU Alexa Fluor™ 488 
Flow Cytometry Assay Kit was used (#C10632, Thermo 
Fisher). After cells were analyzed in the live state for 
A2B5/CD11bc/GLAST or O4/CD11bc/GLAST labelling, 
the remaining triple antibody labelled samples were fixed, 
permeabilized and labeled with Alexa Fluor 488, according 
to the manufacturer’s instructions.
Flow cytometry was performed using an Accuri C6 flow 
cytometer set to a medium flow rate and set volume (50 µL) 
of cells to facilitate comparison of total cell counts across 
treatment conditions and markers. Raw data files were 
extracted to FCS Express (De Novo Software, Glendale, 
CA) for analysis. For live cell flow analysis, an initial gate 
on the healthy (PI-negative), singlet (linear peak area to peak 
width) was applied and used to calculate the total cell count 
within the sample. Microglia were identified based on the 
intensity of the CD11bc signal and the astrocyte population 
was identified based on above threshold GLAST intensity. 
To aid in identifying the A2B5 or O4 positive population, 
the CD11bc(+) and GLAST(+) populations were gated 
out to reveal the oligo-lineage cell population. As with 
the CD11bc(-) and GLAST(+) population, control condi-
tions without antibody labeling allowed for identification of 
threshold setting for the A2B5(+) or O4(+) population. For 
EdU(+) cells, the analysis cell gate was determined by PI(+) 
nuclei along a linear peak area to peak width plot and based 
on the intensity of the Click-It-488 fluorophore.
Duplicate treatments for each treatment condition and 
a minimum of three independent experiments were per-
formed for all reported results. Average cell counts from 
each experiment, treatment and marker were used to calcu-
late overall condition means and standard deviation. A one-
way ANOVA with a Dunnett’s post-hoc statistical analysis 
for comparison to vehicle control conditions was performed 
for each indicated cell marker (GraphPad Software, La Jolla, 
CA).
Total ASM Activity Assay
MGCs were plated on 100 mm petri dishes at a density 
of 10 × 105 cells/cm2 and cultured for 13 days. 10 µg/mL 
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cells in serum containing culture medium, after a complete 
medium change. Alternatively, rHIgM22 or Human IgM 
treatment was performed after washing cells twice with 
DMEM/F12 in modified DMEM/F12 media supplemented 
with N2 supplement (1:100), 2 mM GlutaMax, penicillin/
streptomycin and 0.1% BSA. ASM activity was assessed on 
cell lysates after different times of incubation with rHIgM22 
or isotype control IgM.  [3H]SM (12 pmol) was mixed with 
500 pmol of non-labelled SM, suspended in 0.2% Triton 
X-100 in  CHCl3:CH3OH 2:1 (v/v) and dried under  N2 flux. 
25 µL of 250 mM sodium acetate pH 5.1 were added for 
each sample. MGCs were collected in 0.2% Triton X-100 
in  H2O. 25 µg protein of cell lysates were added to 25 µL 
of reaction substrate and samples were incubated for 2 h at 
37 °C. The reaction was stopped by the addition of 200 µL 
of  CHCl3:CH3OH 2:1 (v/v) followed by centrifugation at 
16,100×g for 20 min. The amount of SM hydrolyzed was 
determined through autoradiography after thin layer chro-
matography separation of the substrate,  [3H]SM, and the 
reaction product,  [3H]ceramide. Negative controls were 
performed using heat-inactivated cell lysates (100 °C for 
3 min).
[3H]Sphingosine Metabolism and Evaluation 
of Cellular and Extracellular S1P
MGCs were plated on 60 mm dishes at a density of 10 × 105 
cells/cm2 and cultured for 13 days, whereas astrocytes were 
plated on 35 mm dishes at a density of 4.5 × 104 cells/cm2 
and cultured for a week before proceeding with the experi-
ment. At the time of the experiment, the medium was gen-
tly removed and cells were incubated for 24 h in medium 
supplemented with 1% FBS in the presence or absence 
of 10 µg/mL control IgM or rHIgM22. At the end of the 
treatments, the cells were pulsed with 20 nM d-erythro-[3-
3H]sphingosine  ([3H]Sph, 0.4 µCi/mL), for 45 min, in the 
presence of medium only, or medium containing control 
IgM or rHIgM22 in the presence or absence of AG1296 
[24–26]. Subsequently, cells were harvested, total lipids 
were extracted at 4 °C with chloroform/methanol, and parti-
tioned by adding 0.1 M  NH4OH, as previously reported [25, 
27]. After centrifugation, the upper alkaline aqueous phase, 
containing intracellular S1P, was evaporated under nitrogen 
stream and associated radioactivity was determined by liquid 
scintillation counting. The methanolized organic phase and 
the aqueous phase were analyzed by HPTLC using chloro-
form/methanol/water (55:20:3 by vol) as solvent system. The 
 [3H]-labeled sphingolipids were recognized and identified as 
previously described.
Extracellular S1P was extracted from pulse medium and 
purified as described elsewhere [24, 25, 28]. Briefly, a two-
step partitioning was performed, first in alkaline conditions 
followed by a back extraction of the aqueous phase obtained 
in acidic conditions. The acidic organic phase obtained, con-
taining S1P, was evaporated under nitrogen stream; the aque-
ous phase, containing tritiated water produced from  [3H]
S1P degradation, was purified by fractional distillation and 
counted for radioactivity [27].
The fractions containing cellular and extracellular S1P 
were submitted to HPTLC separation on silica gel plates 
using n-butanol/acetic acid/water (3:1:1, v/v/v) as solvent 
system. Standard  [3H]S1P was chromatographed on the 
same plate and used as internal standard. At the end of the 
chromatography, HPTLC plates were dried and submitted 
to digital autoradiography (TRacer Beta-Imager, Biospace, 
Paris, FR) and S1P and other radioactive sphingolipids were 
quantified by M3Vison software (Biospace, Paris, FR).
Immunoblotting Analysis
Cells were lysed with lysis buffer (10 mM Tris–HCl pH 7.5, 
150 mM NaCl, 5 mM EDTA, 1 mM  Na3VO4, 1 mM PMSF, 
75 mU/mL aprotinin).
In order to evaluate PDGFαR, SK1, pSK1, and SK2 
expression, cell proteins were resolved by SDS-PAGE 
on 10% polyacrylamide gels and transferred onto PVDF 
membranes. Membranes were then blocked with 3% BSA 
in TBS with 0.05%-Tween20, incubated overnight with 
anti-SK1 (1:1000), anti-pSK1 (1:500), anti-SK2 (1:3000), 
anti-PDGFαR (1:1000), and anti-GAPDH (1:5000) primary 
antibodies and finally with a goat anti-rabbit horseradish per-
oxidase-linked secondary antibody (1:2000) using GAPDH 
as loading control.
In order to evaluate SGPL1 and SPP1 expression, cell 
proteins were resolved by SDS-PAGE on 10% polyacryla-
mide gels and transferred onto PVDF membranes. Mem-
branes were then blocked with 5% Milk in TBS with 0.05%-
Tween20, incubated overnight with anti-SGPL1 (1:500), 
anti-SPP1 (1:500), and anti-GAPDH (1:5000) primary anti-
bodies and finally with a goat anti-rabbit horseradish perox-
idase-linked secondary antibody (1:2000) using GAPDH as 
loading control.
In all cases bound antibodies were visualized by ECL 
(LiteABlot Plus and LiteABlot Turbo Chemiluminescent 
Substrate). For quantitative measurements, membranes 
were acquired by UVITEC Cambridge technology (Eppen-
dorf). Image analysis was performed using NINEAlliance 
software.
Steady‑State Labeling of MGC [1‑3H]sphingosine 
and Lipid Analysis
MGCs were plated on 100 mm petri dishes at a density of 
10 × 105 cells/cm2 and cultured for 13 days. Cell sphingolip-
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chase with 3 × 10−8 M [1-3H]sphingosine as described 
previously.
After 24 h of chase, 10 µg/mL of either rHIgM22 or 
Human IgM (Sigma) were then added to the cells. After 
another 24 h, cells were collected, centrifuged and lysed 
in ice cold water. Following lyophilization, lipids were 
extracted with chloroform/methanol/water, 2:1:0.1, by vol-
ume, subjected to a two-phase partitioning, and radioactive 
lipids were separated by monodimensional HPTLC and 
quantitatively analyzed by digital autoradiography [29].
Other Experimental Procedures
The protein content was determined by the Bio-Rad DC 
assay kit using BSA as the reference standard. Radioactivity 
associated with cells, with medium, and with lipid extracts 
was determined by liquid scintillation counting.
Statistical Analysis
Experiments were run in triplicate, unless otherwise stated. 
Data are expressed as mean value ± SD and were analyzed 
by unpaired Student’s t-test. p Values are indicated in the 
legend of the figures.
Results
Effects of rHIgM22 Exposure on the Proliferation 
of MGCs
The effects of rHIgM22 on growth rates and composition 
of mixed glial cultures was evaluated by flow cytometry 
using antibodies known to identify each of the major cel-
lular components of the culture. CD11bc reactivity was used 
to identify the microglial population, astrocyte-specific glu-
tamate transporter (GLAST) reactivity was used to identify 
the astrocyte population, immature oligodendrocytes (OLs) 
were identified by O4 immunoreactivity and oligodendro-
cyte precursor cells (OPCs) were detected by A2B5 antibody 
reactivity. In addition to immunophenotyping the cultures, 
total cell counts and EdU incorporation was used to assess 
the proliferative state of the culture.
Mixed glial cultures were treated on DIV 5 by replacing 
the culture medium with serum free medium (SFM) contain-
ing rHIgM22 at 1.25, 5.0 or 20 µg/mL, SFM plus the PBS 
vehicle, SFM with a human poly-clonal isotype control IgM 
at 20 µg/mL, or with growth medium containing 10% FBS. 
Cultures were incubated for 48 additional hours after which 
the cell populations were subjected to antibody labeling or 
detection of EdU incorporation as described in the “Material 
and Methods” section. For EdU experiments, the cells were 
treated with 10 µM of EdU for 18 h prior to the cell harvest 
at 48 h post-treatment.
Treatment with rHIgM22 promoted a significant increase 
in the total cell number and EdU incorporation compared 
to the serum free, vehicle control conditions and did so in a 
dose dependent manner (Fig. 1a, b; Table 1). Furthermore, 
rHIgM22 maintained culture growth rates and EdU incor-
poration similar to the serum containing growth medium 
(GM) condition. In contrast, an isotype control IgM had no 
impact on cell proliferation over the course of 48 h as there 
was no difference in cell or EdU number when compared to 
the vehicle control condition.
Immunophenotyping of the cultures following treat-
ment demonstrated a pleotropic effect of rHIgM22 on the 
proliferative rate of all the cells in the culture (Fig. 1c–f; 
Table 1). However, the effect of rHIgM22 on the astrocyte 
(GLAST(+)) and OPC (A2B5(+)) cell population was 
noticeably more pronounced than the effect on CD11bc(+) 
microglia proliferation (Fig. 1e).
Watzlawik and collaborators [20] showed that rHIgM22 
effect on OPC proliferation in mixed glial cultures was medi-
ated by PDGFαR. Thus, we assessed the effect of treatment 
with 10 µg/mL rHIgM22 (an antibody concentration within 
the effective range for the stimulation of astrocyte prolifera-
tion in MGCs) on the PDGFαR protein levels. As shown 
in Fig. 2, rHIgM22 treatment was able to induce a time-
dependent increase in PDGFαR levels, as measured by west-
ern blotting (the maximal effect was a fivefold increase after 
48 h). Treatment with isotype control IgM under the same 
experimental conditions had no effect on PDGFαR levels.
Effect of rHIgM22 Exposure on ASM Activity 
and Ceramide Levels in MGCs
Recent evidence highlights the importance of increased 
ceramide levels in the induction of apoptosis, astrocyte acti-
vation and neuronal damage in MS [30, 31]. In particular, 
ceramide generated from sphingomyelin via the enzyme acid 
sphingomyelinase (ASM) is a key mediator for the detrimen-
tal events observed in mouse models of MS. On the other 
hand, genetic deficiency or pharmacological inhibition of 
Fig. 1  MGCs proliferative response to 48  h rHIgM22 or control 
treatments. Immunophenotyping by flow cytometry of mixed glial 
cell cultures following 48 h of treatment with SFM + vehicle (Veh), 
SFM + isotype control (IC), SFM + IgM22 at 1.25, 5.0 or 20 µg/mL, 
or growth media (GM). Recovered cells were labeled with fluoro-
chrome labeled primary antibodies against the OPC marker A2B5, 
the immature OL marker O4, the microglial marker CD11bc, the 
astrocyte marker GLAST or were processed for the presence of EdU 
incorporation following an 18  h pulse using Click-it detection. Cell 
counts for equal volume of isolated cells was performed for a total, 
b EdU(+), c A2B5(+), d O4(+), e CD11bc(+) or f GLAST(+) cells. 
One-way ANOVA with a Dunnett’s post-hoc analysis was performed 
for each marker versus the vehicle control condition. *p < 0.05, 





























































































Journal : Large 11064 Article No : 2701 Pages : 15 MS Code : NERE-D-18-00460 Dispatch : 17-12-2018
 Neurochemical Research
1 3
ASM effectively protects against demyelination, detrimen-
tal neuroinflammatory response and development of symp-
toms, suggesting that the ASM/ceramide axis is central in 
the onset and progression of the disease [30, 31]. Thus, we 
determined the effect of rHIgM22 or isotype control IgM on 
the total activity of ASM in MGCs by cell-free assay using 
mixed micelles of SM and Triton X-100 as the substrate. 
Antibody treatment was performed either in serum con-
taining medium or in the absence of serum, as described in 
“Materials and Methods”. No SM hydrolysis was detected in 
negative controls performed by incubating heat-inactivated 
samples under the same conditions. After 6 h of incubation, 
in vitro ASM activity was identical in rHIgM22 and control 
cells, and identical to the enzyme activity measured at time 
0. Treatment with either rHIgM22 or control IgM for 24 
and 48 h in the presence of serum determined a significant 
increase in the ASM activity with respect to the starting 
incubation time of 6 h (Fig. 3a). However, the increase of 
ASM activity after 6 h was higher for control-treated cells 
(+ 41% and + 44% at 24 and 48 h, respectively) than for 
rHIgM22-treated cells (+ 25% and + 31% at 24 and 48 h, 
respectively). Thus, in the presence of serum, the enzyme 
activity was slightly but significantly lower in rHIgM22-
treated than in control cells. On the other hand, when anti-
body treatment was performed in the absence of serum 
(the same experimental condition used to assess the effect 
of rHIgM22 on MGCs proliferation), ASM activity was 
Table 1  MGCs proliferative response to 48 h rHIgM22 or control treatments
Data plotted in Fig. 1 have been calculated as percentage respect to vehicle-treated cells (representing 100%) for each treatment for the different 
cell populations
CD11(+) (%) GLAST(+) (%) A2B5(+) (%) O4(+) (%) EdU(+) (%) Total cells (%)
Vehicle 100.0 100.0 100.0 100.0 100.0 100.0
Isotype control 129.2 123.6 95.6 166.4 116.5 122.1
1.25 µg/mL rHIgM22 219.7 201.8 237.4 177.3 324.2 241.8
5.0 µg/mL rHIgM22 265.7 236.2 381.8 260.4 553.4 308.6
20 µg/mL rHIgM22 272.9 239.9 317.7 258.2 570.3 251.5

































Fig. 2  Effect of rHIgM22 or control treatments on the expression of 
PDGFαR in MGCs. MGCs at the 13th day of culture were treated 
with a single dose (10  µg/mL) of rHIgM22 or of a non-immuno-
genic human IgM (as the negative control) for different times (6, 24 
or 48  h). After treatment, cells were harvested, lysed and the same 
amount of protein (50  µg) for each sample was separated by SDS-
PAGE and transferred to PVDF membranes. Membranes were probed 
by western blotting using specific anti-PDGFαR and anti-GAPDH 
antibodies






























































Fig. 3  Effect of rHIgM22 or control treatments on the in vitro activ-
ity of ASM in MGCs. MGCs at the 13th day of culture were treated 
with a single dose (10 µg/mL) of rHIgM22 or of a non-immunogenic 
human IgM (as the negative control) for different times (6, 24 or 
48  h) in serum containing growth medium (a) or in the absence of 
serum (b). After treatments, cells were harvested and lysed in 0.2% 
Triton X-100. Total ASM was assessed in  vitro by determining the 
hydrolysis of SM as mixed micelles as described under “Materi-
als and Methods”. The amount of hydrolyzed SM was determined 
through autoradiography after HPTLC separation of the substrate, 
 [3H]SM, and the reaction product,  [3H]ceramide. Data are expressed 
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constant along time of treatment and not significantly dif-
ferent in rHIgM22-treated versus control IgM-treated cells 
(Fig. 3b). In addition, we measured the levels of radioactiv-
ity incorporated into ceramide after steady state labeling 
with tritiated sphingosine in the presence of serum (Fig. 4a), 
or after pulse labeling with radioactive sphingosine in the 
absence of serum (Fig. 4b). In both cases, radioactive cera-
mide levels were not significantly different in rHIgM22-
treated versus control IgM-treated cells, suggesting that 
rHIgM22 treatment had no effects neither on ceramide levels 
nor on its turnover.
S1P in MGC and Astrocytes
An increasing number of studies demonstrates that the 
sphingolipid mediator S1P, usually exerting biological 
effects opposite to those of ceramide (in particular acting as 
anti-apoptotic stimulus and positive regulator of cell prolif-
eration), is a relevant player in MS [13, 14]. For this reason, 
we evaluated whether rHIgM22 effects could be related to an 
altered production and metabolism of S1P. To this purpose, 
MGCs, treated with or without 10 µg/mL isotype control 
IgM or rHIgM22 for 24 h were submitted to pulse experi-
ments with tritiated sphingosine  ([3H]Sph). After pulse, 
lipids associated with cells and culture media were extracted 
and  [3H]S1P levels were determined as described in “Materi-
als and Methods”. After short time (45 min) pulse, we found 
comparable levels of incorporated radioactivity in untreated, 
control IgM- and rHIgM22-treated cells (608,861.5, 
613,279.5, and 639,040.2 dpm/dish respectively). Both con-
trol IgM and rHIgM22 induced a significant increase of the 
radioactivity associated with intracellular S1P (+ 155% and 
+ 228% respectively) compared to untreated cells (Fig. 5a). 
Similarly, as shown in Fig. 5b, treatment with both control 
IgM and rHIgM22 was able to increase the amount of the 
labeled  [3H]S1P associated with the extracellular milieu 
(+ 32% and + 70% respectively). Of relevance, the amount 
of extracellular  [3H]S1P was significantly higher (by about 
24%) in the rHIgM22-treated cells compared to control IgM-
treated cells.
Since we showed that rHIgM22 treatment was able to 
upregulate the expression of PDGFαR at the protein level 
(Fig. 2), we investigated whether PDGFαR activation might 
be relevant for the increased production and release of S1P in 
MGCs. To this aim, we measured the production and release 
of S1P in MGCs upon treatment with rHIgM22 or control 
IgM in the absence or in the presence of the selective inhibi-
tor of PDGFαR activation, AG1296. As shown in Fig. 6, 
treatment with PDGFαR inhibitor AG1296 had no effect on 
the intracellular  [3H]S1P levels neither in rHIgM22 treated 
nor in control IgM treated cells (Fig. 6a). On the other hand, 
AG1296 treatment strongly inhibited the rHIgM22-induced 
release of  [3H]S1P to the extracellular milieu (− 42% vs. 
rHIgM22-treated cells), while it had no effects on extracel-
lular  [3H]S1P levels in control-treated cells (Fig. 6b).
In the attempt to identify the metabolic source of the 
increased S1P in the MGCs treated with or without IgM and 
rHIgM22, we evaluated whether treated cells could be char-
acterized by different activity and/or expression of the key 
enzymes involved in S1P synthesis and catabolism. We found 
that SK1 and SK2 showed a superimposable expression in 
control IgM-treated and rHIgM22-treated cells (Fig. 7). Since 
SK1 can be activated through ERK1/2-mediated phosphoryla-
tion on  Ser225 [32], we assessed whether the increase in S1P 

























































Fig. 4  Effect of rHIgM22 or control treatments on radioactive sphin-
golipid levels after steady-state or pulse labeling with  [3H]Sphin-
gosine. a Lipid pattern of MGCs treated with 10  µg/mL of either 
rHIgM22 or Human IgM for 24  h. Cell sphingolipids were steady-
state metabolically labeled by 2 h pulse/48 h chase with 3 × 10−8 M 
[1-3H]sphingosine. Cell lipids were extracted with chloroform/metha-
nol/water, 2:1:0.1, by volume, subjected to a two-phase partitioning. 
Organic phases were separated by monodimensional HPTLC using 
chloroform/methanol/water, 110:40:6, by volume, as a solvent system 
and quantitatively analyzed by digital autoradiography. b radioactiv-
ity incorporated into ceramide, glucosylceramide and sphingomy-
elin after short pulse labeling with radioactive sphingosine. MGCs at 
the 13th day of culture were treated with a single dose (10  µg/mL) 
of rHIgM22 or of a non-immunogenic human IgM for 24  h. IgM 
(white bars) and rHIgM22 treated cells (gray bars) were pulsed with 
20 nM  [3H]-Sph (0.4 µCi/mL) for 45 min. At the end of pulse, cells 
were harvested and submitted to lipid extraction and partitioning as 
described in Materials and Methods. The methanolized organic phase 
was analyzed by HPTLC and digital autoradiography of HPTLC 
using chloroform/methanol/water, 55:20:3 by volume. Radioactiv-
ity incorporated in ceramide (Cer), glucosylceramide (GlcCer) and 
sphingomyelin (SM) is shown. All values are the mean ± SD of at 
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SK1 phosphorylation level. To this purpose, we performed 
immunoblotting analysis by using a phospho-specific anti-
body recognizing SK1 (Fig. 7). SK1 phosphorylation was not 
affected by control IgM or rHIgM22 treatment. All together, 
these results suggest that the increased production and release 
of S1P in MGCs does not seem to be mediated by regulation 
of the biosynthetic enzymes, sphingosine kinase 1 and 2. S1P 
levels can be reduced by dephosphorylation due to the activity 
of a specific phosphatase (SPP1), or by cleavage by the S1P 
lyase (SGPL1). SPP1 protein level were unchanged along time 
upon control IgM or rHIgM22 treatment, while SGPL1 levels 
were reduced by ~ 40% in rHIgM22-treated cells versus con-
trol treated cells at 24 h, suggesting that a reduced expression 
of this enzyme could be at least in part responsible for the 
increased S1P release induced by rHIgM22 in MGCs (Fig. 7).
As described above, rHIgM22 treatment was able to 
increase significantly astrocyte proliferation in MGCs, 
while other populations were less or not affected. Fischer 
and collaborators demonstrated that both SK1 and  S1P3 
are upregulated on reactive astrocytes in MS lesions, and 
in cultured astrocytes under pro-inflammatory conditions 
[12]. Thus, we next evaluated S1P production and release 
in the extracellular milieu in purified cultures of astrocytes, 
under the same experimental conditions used for MGCs. 
The levels of incorporated radioactivity after pulse were 
similar in untreated, control IgM- and rHIgM22-treated 
cells (278,543.5, 300,298.4 and 286,312.9 dpm/dish, respec-
tively). As shown in Fig. 8, treatment with 10 µg/mL iso-
type control IgM or rHIgM22 for 24 h did not induce any 
significant change in the production and/or release of S1P 
in pure astrocyte cultures. This result suggest that other cell 
types present in MGCs should be responsible for the release 
of S1P.
Discussion
Naturally occurring antibodies or natural antibodies are 
immunoglobulins detectable in the serum of humans in 


















































Fig. 5  Effect of rHIgM22 or control treatments on the production 
and release of S1P in MGCs. MGCs at the 13th day of culture were 
treated with a single dose (10 µg/mL) of rHIgM22 or of a non-immu-
nogenic human IgM (as the negative control) for 24  h. Untreated 
(black bars), IgM (white bars) and rHIgM22 treated cells (gray bars) 
were pulsed with 20 nM  [3H]-Sph (0.4 µCi/mL) for 45 min. At the 
end of pulse, S1P from cells and media was extracted and analyzed as 
described in “Materials and Methods”. Radioactivity incorporated in 
intracellular (a), and in extracellular S1P (b) is shown. **p < 0.005, 
















































Fig. 6  Effect of AG1296 in rHIgM22 or control-treated cells on the 
production and release of S1P in MGCs. MGCs at the 13th day of 
culture were pretreated 30  min with AG1296 (20  µM) then treated 
with a single dose (10 µg/mL) of rHIgM22 or of a non-immunogenic 
human IgM (as the negative control) for 24 h. IgM (open white bars), 
rHIgM22 treated cells (open gray bars), IgM + AG1296 (hatched 
white bars) and rHIgM22 + AG1296 (hatched gray bars) were pulsed 
with 20 nM  [3H]-Sph (0.4 µCi/mL) for 45 min. At the end of pulse, 
S1P from cells and media was extracted and analyzed as described in 
“Materials and Methods”. Radioactivity incorporated in intracellular 
(a), and in extracellular S1P (b) is shown. **p < 0.005, ***p < 0.001 
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produced by B-cells in a T-cell-independent manner. Fre-
quently, natural antibodies are multivalent and autoreac-
tive. They are part of the innate immune system, however 
their physiological functions are multiple and still not fully 
understood. Nevertheless, it is clear that they are able to 
engage a variety of cell types in human tissues eliciting 
various biological responses [33]. rHIgM22 is the recombi-
nant form of a human monoclonal IgM, sHIgM22, isolated 
from the serum of an individual affected by Waldenström 
macroglobulinemia, a condition characterized by elevated 
production of immunoglobulins. rHIgM22 was established 
after the serendipitous discovery by the group of Rodriguez 
that some natural antibodies, including sHIgM22, were able 
to induce remyelination in animal models of CNS demyeli-
nating disease [34]. rHIgM22 binds to the surface of mor-
phologically differentiated, MBP-positive rat and human 
OLs in culture [15], of O4-positive CG4 cells, to isolated 
myelin and to myelin in live mouse cerebellar slices [35]. 
The hypothesis that OLs represent the main cellular target of 
rHIgM22 was strengthened by the observation that binding 
was abolished in cerebellar slices from mice lacking cer-
ebroside sulfotransferase, the enzyme responsible for the 
Fig. 7  Effect of rHIgM22 or 
control treatments on the protein 
levels and phosphorylation of 
sphingosine kinases in MGCs. 
MGCs at the 13th day of culture 
were treated with a single dose 
(10 µg/mL) of rHIgM22 or of 
a non immunogenic human 
IgM (as the negative control) 
for 2, 6, 12 and 24 h. At the 
end of the treatment cells were 
lysed in 10 mM Tris pH 7.5, 
150 mM NaCl, 5 mM EDTA, 
1 mM  Na3VO4, 1 mM PMSF, 
75 mU/mL Aprotinin. The same 
amount of protein (40 µg) for 
each sample was separated by 
SDS-PAGE and transferred to 
PVDF membranes. Membranes 
were probed by western blotting 
using specific anti SK1, pSK1, 






































































































Fig. 8  Effect of rHIgM22 or control treatments on the production and 
release of S1P in pure astrocyte cultures. Cultured astrocytes were 
treated with a single dose (10 µg/mL) of rHIgM22 or of a non-immu-
nogenic human IgM (as the negative control) for 24  h. Untreated 
(black bars), IgM (white bars) and rHIgM22 treated cells (gray bars) 
were pulsed with 20 nM  [3H]-Sph (0.4 µCi/mL) for 45 min. At the 
end of pulse, S1P from cells and media was extracted and analyzed as 
described in “Materials and Methods”. Radioactivity incorporated in 
intracellular (a), and in extracellular S1P (b) is shown. **p < 0.005, 
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biosynthesis of sulfated glycolipids, the typical myelin lipids 
[36]. rHIgM22 treatment effectively promoted remyelination 
in both immune and non-immune mouse models of demy-
elination [15–19]. Magnetic resonance imaging showed 
that rHIgM22 reached demyelinated spinal cord lesions 
in Theiler’s virus-infected mice, but it did not accumulate 
in CNS of control animals [37]. In humans, rHIgM22 was 
detected in the cerebrospinal fluid of treated MS patients in 
a phase I clinical trial. If we consider the substantial lack of 
treatments able to prevent the progression of demyelinating 
diseases, altogether these observations raise the hope that 
rHIgM22 could be effectively used to stimulate the endog-
enous mechanisms of myelin repair and represent a valuable 
option for the treatment of MS.
While it is clear that the ultimate effect of rHIgM22 is 
increased production of myelin by mature OLs, the mecha-
nisms underlying this effect are still unclear and literature is 
in our opinion quite controversial. Only mature OLs, and not 
OLs at earlier stages of differentiation, neither astrocytes nor 
microglia, showed significant surface binding of rHIgM22 
by immunofluorescence [38]. Early work from the Rodriguez 
group showed that sIgM22, similarly to other remyelination-
promoting monoclonal antibodies, was able to induce  Ca2+ 
transients in different glial populations [39] in rat MGCs. 
In particular, an early and rapid increase in intracellular 
calcium was observed in astrocytes (GFAP-positive cells), 
while a delayed and slower increase in  Ca2+ concentration 
was observed in OPCs and OLs at different stages of differ-
entiation, implying that surface reactivity of this antibody 
is not necessarily a predictor of its biological activity in a 
given cell type. The same group showed that rHIgM22 was 
able to stimulate proliferation of OPCs in MGCs, but not in 
purified OPC cultures [20], suggesting that antibody effect 
on OPC proliferation (and thus on remyelination) might be 
dependent on the recruitment of other cell types present in 
MGCs, i.e., astrocytes and or microglia. The proliferative 
effect of rHIgM22 in MGCs was mediated by the activation 
of PDGFαR, a well-known regulator of OPC proliferation 
and survival. Most glial cell-secreted PDGF is produced by 
astrocytes [40]. However, rHIgM22 treatment of MGCs was 
not able to significantly affect astrocytes and microglia pro-
liferation, even if it slightly increased expression of GFAP 
and of the microglial marker CD68, suggesting some form 
of astrocyte/microglia activation upon rHIgM22 treatment. 
In this paper, we report a marked proliferative response of 
MGCs to rHIgM22 treatment under comparable experimen-
tal conditions (Fig. 1; Table 1). We observed a significant 
proliferative response, especially at higher antibody con-
centrations, in A2B5(+) and O4(+) OPCs, and, at a lesser 
extent, in CD11(+) cells. However, the most significant 
stimulation of proliferation at all antibody concentrations 
tested was observed for GLAST(+) astrocytes (Fig. 1). The 
effect of rHIgM22 on the astrocyte (GLAST(+)) and OPC 
(A2B(+)) cell population appeared to supersede the growth 
potential of serum containing media (GM). We surmise the 
increased numbers of O4-positive cells was a result of the 
proliferation of the OPCs population (A2B5(+)) which in a 
serum-free environment can lead to differentiation towards 
the O4-positive, OL fate. The results of these flow cytom-
etry studies reveal the ability of rHIgM22 to maintain the 
growth potential of mixed glial cultures even in the absence 
of serum and suggests a more prominent function on astro-
cyte and oligodendrocyte precursor cells. Similar results 
have been obtained using imaging-based methods for the 
assessment of cell proliferation.
This is apparently in contrast with the aforementioned 
report showing no apparent proliferation of astrocytes in 
response to rHIgM22 treatment. We have measured the pro-
liferative response as total cell count and EdU labeling index 
by flow cytometry and imaging analysis with consistent 
result, while Watzlawik et al. analyzed the co-localization 
between the nuclear proliferation marker Ki-67 and cell type 
specific markers. This technical difference could explain the 
apparent discrepancy of the results. From this point of view, 
it might be worth to recall that GFAP staining requires cell 
permeabilization, while GLAST staining is performed on 
non permeabilized cells.
Interestingly, we add new pieces of evidence highlighting 
the importance of sphingolipid mediators in rHIgM22 sign-
aling. Ceramide (Cer) and S1P are interconvertible bioactive 
sphingolipids, their levels are finely regulated, and they in 
turn differentially regulate cell growth and survival, modu-
lating opposing signaling pathways. The balance between 
the levels of Cer and S1P, a concept known as “sphingolipid 
rheostat”, and their regulatory effect on different pathways 
determines the fate of the cells [41–43]. In fact, elevation 
of cellular ceramide levels induces cell growth arrest and 
apoptosis [43], whereas S1P production is required for opti-
mal cell proliferation induced by growth factors [44] and 
suppresses ceramide-mediated apoptosis [41]. Treatment 
of MGCs with rHIgM22 induced a slight but significant 
decrease in the in vitro activity of ASM (Fig. 3a), one of the 
major responsible factors for the stimulus-mediated produc-
tion of Cer by SM hydrolysis. Previously it was shown that 
the Src family kinase Lyn (that was activated downstream to 
PDGFαR in MGCs treated with rHIgM22 [20]) associated 
with integrin receptors was able to suppress the activity of 
ASM thus preventing ceramide-induced apoptosis in mouse 
brain and cultured OLs [45]. Remarkably, the importance of 
ASM for the onset and progression of MS has been recently 
highlighted by the finding that genetic deficiency or phar-
macological inhibition of ASM are protective against lesions 
in mouse models of MS [30, 31]. However, the inhibitory 
effect of rHIgM22 on ASM activity was absent in MGCs 
when antibody treatment was performed in the absence of 
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experiments with radioactive sphingosine showed no dif-
ferences in the incorporation of radioactivity into Cer, in 
rHIgM22 treated versus control cells (Fig. 4).
On the other hand, rHIgM22 was able to induce a sig-
nificant increase in the production of S1P and in its release 
in the culture medium in MGCs (Fig. 5). Remarkably, we 
demonstrated that the effect of rHIgM22 on the release of 
S1P from MGCs was strongly inhibited by the concomitant 
treatment with a selective inhibitor of PDGFαR, suggesting 
that antibody-mediated receptor activation is a requisite for 
S1P release. This, together with our finding, that rHIgM22 
was able to upregulate PDGFαR protein levels (Fig. 2) and 
with previous data suggesting that rHIgM22 was able to acti-
vate PDGFαR [20], confirms the importance of PDGFαR as 
a mediator of rHIgM22 biological effects.
Sphingosine kinase 1 and S1P receptors are upregu-
lated in reactive astrocytes in MS lesions. S1P by acting on 
 S1P3 receptors on astrocytes induced the secretion of the 
chemokine CXCL1, which in turn was able to recruit OPCs 
to the lesion area, with a possible positive impact on remy-
elination [6, 12]. Treatment with rHIgM22 on MGCs had 
no effects on the protein levels of SK1 and SK2, or on SK1 
phosphorylation, the main known activation mechanism for 
SK1 (Fig. 7). Among catabolic enzymes responsible for the 
removal of S1P, treatment with rHIgM22 had no effects on 
the protein levels of the specific phosphatase SPP1, while it 
reduced the levels of the S1P lyase SGPL1. To our knowl-
edge, this is the first report indicating the possible role of 
this enzyme in MS and/or mechanisms of myelin repair.
We tested the possibility that S1P production by rHIgM22 
in MGCs could involve astrocytes, implying the possibil-
ity of a S1P-dependent autocrine loop controlling astrocyte 
proliferation in response to the antibody. However, rHIgM22 
treatment under the same experimental condition was not 
able to affect the production or release of S1P in pure cul-
tured astrocytes (Fig. 8). This finding is interesting but not 
particularly surprising considering that the main mode of 
action of extracellular S1P is paracrine rather than autocrine. 
In addition, rHIgM22 did not show significant binding to 
cultured astrocytes, and astrocytes express very low lev-
els of sulfated antigens, that seem relevant for the binding 
of rHIgM22. Thus, another cellular population present in 
MGCs is likely involved in this event. S1P-producing cells 
in response to rHIgM22 remain to be identified. However, 
microglia seems to play very important roles in the lesion 
microenvironment. As for astrocytes, rHIgM22 did not show 
significant surface binding to microglia by immunofluores-
cence [38]. However, a recent paper showed that rHIgM22 
can stimulate myelin phagocytosis by microglial cells, a cru-
cial event in clearing the myelin debris that strongly inhibits 
OPCs maturation [9]. Thus, it is becoming evident that the 
myelin-repair effect of rHIgM22 requires the orchestration 
of the responses of multiple cellular populations in the lesion 
niche. The data presented here suggest that the balance 
between different sphingolipid mediators in the sphingolipid 
rheostat might play a significant role in this orchestration.
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